Comparable stake leader
Matthew Angel
SEC ownership of Tempest Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001544227.
Disclosed value leader
Matthew Angel
Comparable rows
22/38
Latest evidence
30 Jun 2026
- Public ticker
- TPST on Nasdaq
- Parsed ownership sources
-
3/4/5, 13D/G, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Matthew Angel
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
22 of 38
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Matthew Angel
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001544227
- Issuer location
- Brisbane, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Tempest Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Matthew Angel
Disclosed value leader
Matthew Angel
Comparable rows
22/38
Latest evidence
30 Jun 2026
3/4/5
13D/G
13F
Lead comparable stake: 37%
16 rows are not safely comparable across share classes.
13D/G row: Matthew Angel
Showing 1-8 of 38 holder rows.
Quick read
Matthew Angel leads the comparable SEC ownership view at 37%.
22 of 38 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Matthew Angel's linked filing trail.
Comparable ownership
Top 5
Matthew Angel
37%
SABBY MANAGEMENT, LLC
9.9%
Versant Venture Capital VI, L.P.
1.1%
Versant Venture Management, LLC
1.8%
VANGUARD CAPITAL MANAGEMENT LLC
1.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 38 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Matthew Angel |
3/4/5
13D/G
CEO and President, Director, 10%+ Owner
|
37%
from 13D/G
|
$38,112,971
14,069,632 shares
mixed-class rows
|
+$1,000,002 | 24 Mar 2026 |
| SABBY MANAGEMENT, LLC |
13D/G
13F
Company
|
9.9%
|
$1,397,913
492,223 shares
|
$0 | 31 Dec 2025 |
| Versant Venture Capital VI, L.P. |
3/4/5
13D/G
10%+ Owner · Versant Vantage II, L.P.
|
1.1%
from 13D/G
|
$2,562,608
2,328,585 shares
|
— | 08 Aug 2024 |
| Versant Venture Management, LLC |
13F
Company
|
1.8%
|
$299,447
269,772 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
1.7%
|
$259,616
233,888 shares
|
— | 30 Jun 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.64%
|
$96,155
86,625 shares
|
— | 30 Jun 2026 |
| VANGUARD FIDUCIARY TRUST CO |
13F
Company
|
0.51%
|
$76,488
68,908 shares
|
— | 30 Jun 2026 |
| BlackRock, Inc. |
13F
Company
|
0.29%
|
$43,365
39,068 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$1,000,002.
Buys
$1,000,002
Insiders: 1
Sells
$0
Insiders: 0
Net
+$1,000,002
Shares: +462,964
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 462,964
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 462,964 | 0 | $1,000,002 | $0 | +$1,000,002 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-18 of 18 reporting-owner rows connected to Tempest Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
18
Largest Forms 3/4/5 holder
Matthew Angel
Net 12M change
+$1,000,002
Latest report
04 Jun 2026
Recent insider transactions for Tempest Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| John David Yee | TPST | Stock Option (right to buy) | Award | 25,000 | 25,000 | 04 Jun 2026 | Direct | |||
| William Drake Richey | TPST | Stock Option (right to buy) | Award | 25,000 | 25,000 | 04 Jun 2026 | Direct | |||
| Justin Trojanowski | TPST | Employee Stock Option (right to buy) | Award | 22,000 | 22,000 | 31 Mar 2026 | Direct | |||
| Nicholas Maestas | TPST | Employee Stock Option (right to buy) | Award | 140,000 | 140,000 | 31 Mar 2026 | Direct | |||
| Matthew Angel | TPST | Common Stock | Purchase | $500,001 | $2.16 | 231,482 | 231,482 | 24 Mar 2026 | By Factor Bioscience Inc. | |
| Matthew Angel | TPST | Series B Warrant (right to buy) | Purchase | 231,482 | 231,482 | 24 Mar 2026 | By Factor Bioscience Inc. | |||
| Matthew Angel | TPST | Series A Warrant (right to buy) | Purchase | 231,482 | 231,482 | 24 Mar 2026 | By Factor Bioscience Inc. | |||
| Matthew Angel | TPST | Common Stock | Purchase | $500,001 | $2.16 | 231,482 | 231,482 | 24 Mar 2026 | By Factor Bioscience Inc. | |
| Matthew Angel | TPST | Employee Stock Option (right to buy) | Award | 269,621 | 269,621 | 04 Feb 2026 | Direct | |||
| Ronit Simantov | TPST | Stock Option (right to buy) | Award | 1,230 | 1,230 | 27 Jan 2026 | Direct | |||
| Michael Raab | TPST | Stock Option (right to buy) | Award | 1,230 | 1,230 | 27 Jan 2026 | Direct | |||
| Geoffrey Nichol | TPST | Stock Option (right to buy) | Award | 1,230 | 1,230 | 27 Jan 2026 | Direct | |||
| Christine A. Pellizzari | TPST | Stock Option (right to buy) | Award | 1,230 | 1,230 | 27 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.